Comprehensive assessment of efficacy, tolerability and safety of a third-generation combined hormonal contraceptive

Planning for pregnancy and delaying pregnancy without health consequences are especially challenging today. Combined hormonal contraceptives are among the most effective methods of preventing unwanted pregnancies, providing high contraceptive reliability, availability and ease of use, safety and reversibility, as well as therapeutic and preventive action in various states. However, according to the State Statistics Committee of Russia, hormonal contraception is used only by 13.4% of women (2009) in this country. This is caused by suspicions both of patients and physicians about side effects of hormonal contraceptives and feasibility of the method in general.

комбинированная гормональная контрацепция, диеногест, эстрадиола, валерат, приемлемость контрацептивов, лечебные эффекты гормональных контрацептивов, межменструальные кровянистые выделения, Клайра, combined hormonal contraception, dienogest, estradiol vale

1. Прилепская В.Н., Межевитинова Е.А. с соавт. Гормональная контрацепция, 2011.

2. Прилепская В.Н. Лечебные возможности гормональной контрацепции. Русский медицинский журнал, 1999; 1, 2: 1-5.

3. Информационное письмо для практических врачей АГЭ 2011 г.

4. Gupta SK, Gupta N, Suman P et al. Zonapellucida-based contraceptive vaccines for human and animal utility. J Reprodlmmunol. 2011 Mar: 88(2): 240-246.

5. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestra-diol 15 microg. Eur J Contracept Reprod Health Care 1999; 4(Suppl. 2): 9-15.

6. Ahrendt HJ, Nisand I, Bastianelli C et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006; 74(6): 451-457.

7. Palacios S, Wildt L, Parke S et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol 2010; 149: 57-62.

8. Archer DF, Lasa IL. Tailoring combination oral contraceptives to the individual woman. J Womens Health (Larchmt). 2011 Jun; 20 (6): 879-891.

9. David PS, Boatwright EA, Tozer BS, Verma DP, Blair JE, Mayer AP et al. Hormonal contraception update. Mayo Clin Proc 2006; 81: 949-954.

10. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization; 2004.

11. Nahum GG, Parke S, Efficacy and tolerability of a new oral contraceptivecontaining estradiol and dienogest ObstetGynecol 2008; 111(4 Suppl.).